UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Registrant’s telephone number, including area code +62 21 5060 8747

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Underwriting Agreement

On August 14, 2025, NusaTrip Incorporated, a Nevada corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cathay Securities, Inc., as the representative of the underwriters named on Schedule A thereto (the “Representative”), relating to the Company’s initial public offering (the “Offering”) of 3,750,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (“Common Stock”). Pursuant to the Underwriting Agreement, in exchange for the underwriters’ firm commitment to purchase the Firm Shares, the Company agreed to sell the Firm Shares to the underwriters at a purchase price (the “Offering Price”) of $3.72 (93% of the public offering price per share of $4.00, after deducting underwriting discounts and before deducting a 1% non-accountable expense allowance). The Company also granted the underwriters a 45-day over-allotment option to purchase up to an additional 562,500 shares of Common Stock (the “Over-Allotment Shares,” and collectively with the Firm Shares, the “Shares”) at the Offering Price, less the non-accountable expense allowance, from the Company, representing 15% of the Firm Shares. The Company also agreed to issue the Representative warrants to purchase a number of shares of Common Stock which is equal to 7.0% of the aggregate number of shares of Common Stock sold in the Offering, including the Over-Allotment Shares (the “Representative’s Warrants”). The Representative’s Warrants will have an exercise price of $5.00 per share, which is equal to 125% of the Offering Price, subject to adjustment, a cashless exercise provision, and may be exercised for a period of five (5) years following the date of commencement of sales of the Offering, in whole or in part.

The closing of the Offering took place on August 18, 2025. At the closing, the Company sold the Firm Shares for total gross proceeds of $15 million. After deducting underwriting discounts and commissions, the non-accountable expense allowance, and other expenses from the Offering, the Company received net proceeds of approximately $13.5 million. The Company also issued the Representative’s Warrants to the Representative for the purchase of up to 301,875 shares of Common Stock.

The offer and sale of the Shares, and the issuance of the Representative’s Warrants, were registered pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-285997), as amended (the “Registration Statement”), initially filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2025, and declared effective by the SEC on August 8, 2025, and by means of the final prospectus, dated August 14, 2025, filed with the SEC on August 14, 2025 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds from the Offering for mergers and acquisitions, expansion of market, and general working capital and other corporate purposes.

The Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the underwriters, including for liabilities under the Securities Act, other obligations of the parties, and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.

The Underwriting Agreement and the Representative’s Warrants are filed as Exhibit 1.1 and Exhibit 4.1, respectively, to this Current Report on Form 8-K (this “Current Report”), and the description of the material terms of the Underwriting Agreement and the Representative’s Warrants are qualified in their entirety by reference to such exhibits.

Item 8.01. Other Events.

On August 14, 2025, the Company issued a press release announcing the pricing of the Offering. On August 18, 2025, the Company issued a press release announcing the closing of the Offering. Copies of the press releases are attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report, respectively.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATTACHMENTS / EXHIBITS

EX-1.1

EX-4.1

EX-99.1

EX-99.2

XBRL SCHEMA FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: form8-k_htm.xml